Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 66

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 66
---
1,540,956 Total liabilities and stockholders’ equity$1,555,518 $1,663,199 

See accompanying Notes to Condensed Consolidated Financial Statements.

1

Table of Contents    

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended March 31,(In thousands, except share and per share data)20252024Revenues:Product revenue, net$8,726 $8,189 Total revenue8,726 8,189 Operating expenses:Cost of sales$1,085 $627 Research and development72,743 68,620 Selling, general and administrative41,527 31,014 Total operating expenses115,355 100,261 Loss from operations(106,629)(92,072)Interest income, net16,087 8,889 Other income, net1,253 1,634 Net loss$(89,289)$(81,549)Net loss per share - basic and diluted$(1.55)$(1.45)Weighted-average number of common shares used in computing net loss per share – basic and diluted57,459,195 56,383,475 

See accompanying Notes to Condensed Consolidated Financial Statements.

2

Table of Contents    

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

Three Months Ended March 31,(In thousands)20252024Net loss$(89,289)$(81,549)Other comprehensive income (loss)Unrealized gain (loss) on available-for-sale securities1,883 (646)Comprehensive loss$(87,406)$(82,195)

See accompanying Notes to Condensed Consolidated Financial Statements.

3

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Stockholders' Equity

(Unaudited)Common StockAdditionalPaid-InCapitalAccumulatedOtherComprehensiveLossAccumulatedDeficitTreasury StockTotalStockholders’Equity(in thousands, except share amounts)SharesAmountSharesAmountBalance at December 31, 202473,372,696 $73 $2,493,811 $(1,518)$(148,924)(16,216,411)$(802,486)$1,540,956 Unrealized gain on available-for-sale securities— — — 1